Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Retrospective evaluation of the gel stent for surgical management of glaucoma: the Ab Externo Approach
Author Affiliations & Notes
  • Davinder Grover
    Glaucoma Associates of Texas, Dallas, Texas, United States
  • Zena Salim
    Kaiser Permanente Northern California, Oakland, California, United States
  • Ronald S Fellman
    Glaucoma Associates of Texas, Dallas, Texas, United States
  • Khaled Moumneh
    Touro College of Osteopathic Medicine, New York City, New York, United States
  • William J Feuer
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Davinder Grover, Aerie Pharmaceuticals (C), Alcon (F), Allergan (F), Bausch & Lomb (C), Glaukos (C), MicroOptx (C), New World Medical (C), Reichert (C); Zena Salim, None; Ronald Fellman, None; Khaled Moumneh, None; William Feuer, None
  • Footnotes
    Support  Allergan Research Grant
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 945. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Davinder Grover, Zena Salim, Ronald S Fellman, Khaled Moumneh, William J Feuer; Retrospective evaluation of the gel stent for surgical management of glaucoma: the Ab Externo Approach. Invest. Ophthalmol. Vis. Sci. 2020;61(7):945.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate outcomes with the XEN45 gel stent via an Ab Externo approach

Methods : Retrospective chart review. IOPs and numbers of IOP lowering medicines (NMed) were censored following reoperation. High baseline IOP defined as preop IOP ≥ 18mmHg. Postop hypotony defined as 2 or more visits with IOP ≤5mmHg at/after 1 month. Failure in the high IOP group defined as reoperation to control IOP or two consecutive follow up visits at/after month 1 with IOP >21 or not reduced by 20%; high IOP failure in the low baseline IOP group defined as reoperation to control IOP or two consecutive follow up visits at/after month 1 with IOP > than baseline IOP

Results : 60 eyes of 57 patients with ≥3 months follow up were analyzed. Follow up ranged from 3.3 to 8.1 months (median=5.9 months) with 43 (72%) eyes contributing a 6 month visit. Age ranged from 34 to 89 years(mean=73.9) and 32 (56%) were female. 46 (77%) eyes had POAG. Preoperative IOP averaged 19.4 (SD=6.6, range = 9, 48) mmHg and NMed averaged 3.5 (SD=1.4, range = 1, 8). 34 (57%) of eyes had high preoperative IOP.
7 eyes underwent reoperation for IOP control. The cumulative 6 month Kaplan-Meir reoperation rate was 18% in the high IOP group and 4% in the low IOP group. One eye in the high IOP group had hypotony. Failure to control IOP was observed in 8 (23%) and 7 (27%) of eyes in the high and low baseline IOP groups, respectively. 10 (29%) and 7 (27%) of eyes required needling in the high and low baseline IOP groups, respectively. 3 (18%) of the needled eyes required a reoperation to control pressure.
Average IOP was lowered 5.2mmHg, 3.7mmHg, and 6.1mmHg at postop months 1, 3, and 6, respectively (all p ≤ 0.001). At the 1, 3, and 6 month visits, average IOP reductions ranged from 8.0 to 11.0 mmHg in the high baseline IOP group compared to reductions ranging from -0.5 to 1.7mmHg in the low baseline IOP group (all p<0.001).
Average numbers of IOP lowering meds required was lowered by 2.9, 2.3, and 2.2 at postop months 1, 3, and 6, respectively (all p<0.001).
Complications noted at M01 included hyphema with IOP spike (n=2) and blockage of implant (n=1), at M03 included shallow AC (n=7) and hypotony (n=1) and at M06 included IOP spike (n=1) and blockage of tip (n=1).

Conclusions : The gel stent, when performed via an ab externo approach appears to be safe and effective. The results are similar to the previously published results for ab interno implantation

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×